HomeAI · summaries
Storia in 9 fonti
FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL
Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous familial hypercholesterolemia.Enlicitide (Lipfendra), a novel macrocyclic peptide, is the first oral PCSK9 inhibitor FDA-approved to lower LDL, according to press releases from the company and the FDA.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Merck wins first approval of a PCSK9 cholesterol pill
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.
- ·
healio.com
FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL
Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous…
- ·
endpoints.news
Merck beats AstraZeneca to first approval for first PCSK9 pill
Merck's Lipfendra beats AstraZeneca's laroprovstat to become the first oral PCSK9 pill, priced at $10.50/day with $370M in 2027 sales forecast.
- ·
medpagetoday.com
FDA Approves First PCSK9 Inhibitor in Pill Form
With enlicitide, large LDL cholesterol reductions possible without a needle
- ·
nbcnews.com
FDA approves new kind of cholesterol pill
Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way than a statin to lower cholesterol.
- ·
perfil.com
La FDA aprobó la primera pastilla que promete mejorar significativamente el tratamiento del colesterol alto
El organismo regulador de medicinas de los EE. UU. autorizó el uso recetado de “enlicitide”. Este medicamento reduce en hasta un 60% el colesterol LDL y ofrece una alternativa a…
- ·
benzinga.com
FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio - Merck & Co (NYSE:MRK)
Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL cholesterol after positive Phase 3 results.
- ·
economictimes.indiatimes.com
Merck gets US FDA nod for first-in-its-class oral cholesterol drug
The U.S. FDA has approved Merck's new cholesterol-lowering pill, Lipfendra. This oral medication works by blocking the PCSK9 protein, which helps lower bad cholesterol. Lipfendra…
- ·
upi.com
FDA approves first pill to significantly lower 'bad' cholesterol - UPI.com
The Food and Drug Administration on Thursday approved Merck's Lipfendra, which some have hailed as a breakthrough in cholesterol management.